Core Viewpoint - Lianhuan Pharmaceutical (600513) forecasts a net profit loss for 2025, estimating a range between -99 million to -83 million yuan, indicating a shift from profit to loss year-on-year [1] Financial Performance - The company expects a significant decline in net profit and net profit excluding non-recurring items compared to the previous year [1] - The anticipated loss is attributed to multiple factors, including pressure on gross margins from major products due to national drug procurement and adjustments in medical insurance payment policies [1] Operational Factors - Despite maintaining stable overall operations, the company faces increased competition in international markets, which has further impacted profitability [1] - Administrative penalties have resulted in non-recurring expenditures, contributing to the financial downturn [1] R&D Investments - The company has been increasing its investment in research and development, particularly in innovative drugs, leading to higher R&D expenses and related costs [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, is expected to report a significant decline in net profit for the year 2025, transitioning from profit to loss due to various adverse factors [1]. Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between -99 million RMB and -83 million RMB, indicating a shift from profit to loss [1]. - The estimated net profit excluding non-recurring items is expected to range from -39 million RMB to -32.5 million RMB, representing a decrease of 82.368 million RMB to 88.868 million RMB compared to the previous year [1]. Operational Factors - The company's overall operations remain stable; however, it faces pressure on gross margins for its main products due to national drug procurement policies, adjustments in medical insurance payment policies, and intensified competition in international markets [1]. - The company has incurred non-recurring expenses due to administrative penalties, which have contributed to the decline in net profit [1]. - Increased investment in research and development for innovative drugs has led to a rise in R&D expenses and related costs, further impacting profitability [1].